ClinicalTrials.gg
Not yet recruitingNCT07860255Updated Oct 6, 2026

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

A Phase 1 interventional study of Pasritamig in Prostate Cancer, sponsored by Fred Hutchinson Cancer Center. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Fred Hutchinson Cancer Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center — 8 open to participants now, 8 under way, none of them phase 3. Prostatic Neoplasms · Fred Hutchinson Cancer Center.

Planned enrollment
10th of 13
18 · median 48
Started
2026
with 2 others
Phase 1
3 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, and was the 13th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to provide prior to any study specific procedures.
  • Age ≥ 18 years.
  • Documented confirmed adenocarcinoma of the prostate:

    • Unfavourable intermediate risk:

      --- Grade Group 1 with PSA 10-20 ng/mL, T2b-T2c OR Grade Group 2 with PSA 10-20 ng/mL, T2b-T2c, and/or ≥50% cores positive OR Grade Group 3 with PSA \<20 ng/mL.

    • High-risk localized prostate cancer with no very-high-risk features and exactly one high-risk feature:

      • T3a OR
      • Grade Group 4 or 5 OR
      • PSA > 20 ng/dL
    • Very high-risk localized prostate cancer. At least one of the following:

      • T3b-T4
      • Primary Gleason pattern 5
      • 2 or 3 high-risk features
      • >4 cores with Grade Group 4 or 5
  • Negative for distant on conventional (i.e. CT bone scan) and PSMA PET imaging within 60 days of enrollment. Patients with evidence of non-measurable (i.e. per v1.1) metastatic lymphadenopathy as detected by PSMA PET will be eligible if ≤3 radiation isocenters are detectable.
  • performance (ECOG) status 0-1.
  • Eligible and planned for radical prostatectomy.
  • Must have adequate archival biopsy tissue available for KLK2 assessment.
  • Participants who are sexually active with a partner of or a pregnant partner must agree to use , including a condom, during study treatment and for at least 6 months after the last dose of pasritamig. Participants must also agree not to donate sperm during study treatment and for at least 6 months after the last dose of pasritamig.
  • Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • ≥ 9 g/dL with no blood transfusion in the past 28 days
    • (ANC) ≥1.5 × 10⁹/L; however, participants with documented Duffy-null associated neutrophil count or other benign chronic neutropenia may be eligible with ANC ≥1.0 × 10⁹/L if clinically stable and without a history of recurrent or severe infections, at the discretion of the investigator. count ≥ 100 x 109/L
    • Total ≤1.5 × institutional (ULN), except participants with known or suspected Gilbert syndrome may be eligible with total bilirubin ≤3 × ULN, provided direct bilirubin is ≤1.5 × ULN and there is no clinical evidence of hepatic dysfunction. (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN
    • Patients must have estimated of ≥30 mL/min:

      • Estimated creatinine clearance = (140-age [years]) x weight (kg) / serum creatinine (mg/dL) x 72

Exclusion criteria

Exclusion Criteria:

  • Subjects with small cell or neuroendocrine prostate cancer.
  • Active infection or condition that requires treatment with systemic antibiotics within 7 days prior to the first dose of study treatment. Prophylactic anti-infective agents are allowed.
  • Solid organ or bone marrow transplantation.
  • Suspected or known allergies, , or intolerance to of pasritamig (refer to the latest IB for pasritamig).
  • Received doses of systemic medications, such as (doses >10 mg/day prednisone or equivalent) within 3 days prior to the first dose of study treatment. A single course of glucocorticoids is permitted as prophylaxis for imaging contrast (i.e., for participants with allergies to contrast). If glucocorticoids were used to treat immune-related adverse events associated with prior therapy, ≥7 days must have elapsed since the last dose of corticosteroid.
  • Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment. Live, attenuated influenza vaccines are permitted as late as 7 days before the study treatment.
  • Distant based on conventional imaging (clinical stage M1) and PSMA PET within 60 days of enrollment. Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Participants are considered eligible only if the central radiological review confirms clinical stage M0. As noted above, non-measurable nodal metastases detected on PSMA PET will be allowed to enroll if radiation isocenters are detectable.
  • cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles) is excluded.
  • Prior androgen deprivation therapy or other systemic treatment for prostate cancer.
  • Prior treatment with KLK2-targeted therapy and/or with any CD3-directed therapy
  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. This includes, but not limited to, the following:

    • Patients with positive titers or active hepatitis (i.e., or C) due to risk of transmitting the infection through blood or other body fluids.
    • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of to participate in this study.
    • Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
  • Any of the following within 6 months prior to first dose of study treatment:

    • Myocardial infarction,
    • Severe or unstable angina,
    • ventricular arrhythmias,
    • Congestive heart failure ( class II to IV),
    • ,
    • Cerebrovascular accident
  • Active disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications (e.g., chronic corticosteroid, methotrexate, or tacrolimus).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Pasritamig

    Participants receive pasritamig IV on days 1, 8, 15, and 57. Participants then undergo standard of care radical prostatectomy. Participants also undergo blood and tissue sample collection on study.

    Drug: Pasritamig

Interventions

06

What researchers measure

Primary outcomes

  1. Feasibility of neoadjuvant pasritamig

    Proportion of participants who complete planned neoadjuvant pasritamig and undergo radical prostatectomy within the protocol-defined surgical window without treatment-related delay.

    Time frame: From first dose through radical prostatectomy, approximately 70 days

  2. Change in intratumoral CD3+ T-cell density

    Measured as CD3-positive T cells per mm² of evaluable tumor area

    Time frame: Baseline to radical prostatectomy, approximately 70 days

Secondary outcomes

  1. Adverse pathologic features

    Number and proportion of evaluable participants with extraprostatic extension (≥ypT3a), seminal vesicle invasion (ypT3b), regional lymph node involvement (ypN1), positive surgical margins, and any adverse pathologic feature.

    Time frame: At radical prostatectomy, approximately Day 70

  2. Change in prostate-specific antigen (PSA)

    Time frame: Screening through approximately 12 weeks following radical prostatectomy

  3. Time to biochemical recurrence or death

    Time from radical prostatectomy to biochemical recurrence or death, whichever occurs first. Biochemical recurrence is defined as postoperative PSA ≥0.2 ng/mL, confirmed by a second PSA ≥0.2 ng/mL when clinically feasible.

    Time frame: From radical prostatectomy through up to 3 years of follow-up

  4. Pathologic complete response (pCR)

    Proportion of evaluable participants with no residual viable tumor identified on standard H\&E evaluation of the radical prostatectomy specimen.

    Time frame: At radical prostatectomy, approximately Day 70

  5. Pathologic downstaging

    Proportion of evaluable participants with a lower pathologic T stage at radical prostatectomy compared with baseline clinical T stage.

    Time frame: At radical prostatectomy, approximately Day 70

  6. Proportion of participants with pathologic minimal residual disease (pMRD)

    Proportion of evaluable participants with residual viable carcinoma ≤5 mm in the greatest dimension of the largest residual tumor lesion and prostate-confined, lymph-node-negative disease (≤ypT2, ypN0).

    Time frame: At radical prostatectomy, approximately Day 70

  7. Pathologic minimal residual disease (pMRD)

    pMRD is defined as residual viable carcinoma ≤5 mm in the greatest dimension of the largest residual tumor lesion with ≤ypT2 and ypN0 disease.

    Time frame: At radical prostatectomy, approximately Day 70

  8. Residual cancer burden (RCB)

    RCB will also be quantified, with favorable RCB defined as ≤0.25 cm³ with ≤ypT2 and ypN0 disease.

    Time frame: At radical prostatectomy, approximately Day 70

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 24 months is below that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860255
Collaborators
Johnson & Johnson
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Fred Hutch Immunotherapy Intake
Contact
immunotherapy@fredhutch.org
206-606-4668
Steven Blinka, MD, PhD
principal investigator · Fred Hutchinson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pasritamig

Start the discussion